TheEdgeResearch
Home / Stocks / BTMD

biote Corp. (BTMD)

NASDAQ Healthcare Medical - Care Facilities
$1.22 ▼ -0.81%
Market Cap
$53.8M
Sector
Healthcare
Industry
Medical - Care Facilities
Beta
1.61
52-Wk Range
1.205-3.26
CEO
Robert C. Peterson
Country
US
Currency
USD

biote Corp. operates in the Medical - Care Facilities industry of the Healthcare sector, headquartered in Irving, TX, US. The stock last traded at $1.22, down 0.81% on the session, giving a market capitalisation of $53.8M. On trailing twelve-month figures it carries a trailing P/E of 7.27, a net margin of 3.2%. Its beta of 1.61 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
7.27
Price / Sales
0.29
Price / Book
-0.53
EV / EBITDA
7.30
Gross margin
60.2%
Operating margin
8.0%
Net margin
3.2%
Return on equity
—
Debt / equity
-1.96
Current ratio
1.43
Dividend yield
0.0%
Payout ratio
2.5%
Company profile
Exchange
NASDAQ Global Market
Employees
223
IPO date
2021-04-28
Headquarters
Irving, TX, US
About biote Corp.

Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.

Comparable companies

biote Corp. is most often compared with the following Healthcare names:

ABOSACTUANIKINOJYNTLUCDMCRBSCLXSPROVOR
More research on BTMD
BTMD technical analysis BTMD TheEdge Score Compare against peers
Open full interactive analysis & DCF →